Application of signal transduction inhibition as a therapeutic strategy for central nervous system tumors

Pediatric Neurosurgery

Volumn 29, Issue 5, 1998, Pages 228-244

  Pollack, Ian F ^a,b   Bredel, Markus ^a   Erff, Melanie ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Astrocytoma; Cell proliferation; Growth factor; Protein kinase C; Signal transduction

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CALPHOSTIN C; CISPLATIN; CYTOTOXIC AGENT; ETOPOSIDE; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE; TAMOXIFEN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; GLIOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; ENZYME INHIBITORS; GENES, RAS; GLIOMA; HUMANS; PROTEIN KINASE C; SIGNAL TRANSDUCTION;

EID: 0032422490     PISSN: 10162291     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028729     Document Type: Article

References (213)

1. Burger PC, Scheithauer BW, Vogel FS: Surgical Pathology of the Nervous System and Its Coverings, ed 3. New York, Churchill Livingstone, 1991, pp 194-271.
2. Pollack IF: Current concepts in the diagnosis and treatment of pediatric brain tumors. N Engl J Med 1994;331:1500-1507.
3. Sidransky D, Mikkelsen T, Schechheimer K, Rosenblum ML, Cavenee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 1992;355:846-847.
4. Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin R, Bozik ME, Gollin SM: The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 1997;57:304-309.
5. Deimling A von, Louis DN, Wiestler OD: Molecular pathways in the formation of gliomas. Glia 1995;15:328-338.
6. Reifenberger G, Ichimura K, Reifenberger J, Elkahloun AG, Meltzer PS, Collins VP: Refined mapping of 12q13-q15 amplicons in malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res 1996;56:5141-5145.
7. Louis DN: A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997;7: 755-764.
8. Deimling A von, Louis DN, Ammon K von, Petersen I, Hoell T, Chung RY, Martuza R, Schoenfeld D, Yasaragil MG, Wiestler OD, Seizinger BR: Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 1992;77:295-301.
9. James CD, Carblblom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP, Cavenee WK: Clonal genomic alterations in glioma malignancy stages. Cancer Res 1988;48:5546-5551.
10. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Gen 1997;15:356-362.
11. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor in primary human brain tumors of glial origin. Nature 1984;313:144-147.
12. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987;84:6899-8903.
13. Aaronson SA: Growth factors and cancer. Science 1991;254:1146-1153.
14. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Jr: Response of malignant glioma cell lines to epidermal growth factor and platelet-derived growth factor in a serum-free medium. J Neurosurg 1990;73: 106-112.
15. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Jr: Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways. J Neurosurg 1991;75:284-293.
16. Schober R, Bilzer T, Waha A, Reifenberger G, Wechsler W, von Deimling A, Wiestler OD, Westphal M, Kembshead JT, Vega F, et al: The epidermal growth factor receptor in glioblastoma: Genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin Neuropathol 1995;14:169-174.
17. van der Valk P, de Moor I, Kamphorst W, Meijer CJ: Autocrine and paracrine growth in gliomas (abstract). J Pathol 1995;175(suppl): 106.
18. Vassbotn FS, Ostman A, Langeland N, Holmsen H, Westermark B, Heldin CH, Nister M: Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line. J Cell Physiol 1994;158:381-389.
19. Werner MH, Humphrey PA, Bigner DD, Bigner SH: Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines. Acta Neuropathol 1988;77:196-201.
20. Westphal M, Brunken M, Rohde E, Herrmann H-D: Growth factors in cultured human glioma cells: Different effects of FGF, EGF, and PDGF. Cancer Lett 1988;38:283-296.
21. Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades NH: Co-expression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest 1990;86:131-140.
22. Nister M, Claesson-Welch L, Eriksson A, Heldin C-H, Westermark B: Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem 1991;266:16755-16763.
23. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP: Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991;51:2164-2172.
24. Morrison RS, Yamaguchi F, Saya H, Bruner JM, Yahanda AM, Donehower LA, Berger M: Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neurooncol 1994;18:207-216.
25. Gross JL, Herblin WF, Dusak BA, Czerniak P, Diamond MD, Sun T, Eidsvoog K, Dexter DL, Yayon A: Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J Natl Cancer Inst 1993;85:121-131.
26. Gammeltoft S, Ballotti R, Kowalski A, Westermark B, van Obberghen E: Expression of two types of receptor for insulin-like growth factors in human malignant glioma. Cancer Res 1988; 48:1233-1237.
27. Glick RP, Unterman TG, Hollis R: Radioimmunoassay of insulin-like growth factors in cyst fluid of central nervous system tumors. J Neurosurg 1991;74:972-978.
28. Feldkamp MM, Rak J, Lau N, Kerbel RS, Guha A: Astrocytomas express high levels of vascular endothelial growth factor (VEGF) which are reduced through Ras pathway inhibition. Clin Neurol Neurosurg 1997;99:A5.
29. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:574-579.
30. Weiner HL: The role of growth factor receptors in central nervous system development and neoplasia. Neurosurgery 1995;37:179-194.
31. Evans VG: Multiple pathways to apoptosis. Cell Biol Int 1993;17:461-476.
32. Denmeade SR, Isaacs JT: Programmed cell death (apoptosis) and cancer chemotherapy. Cancer Control 1996;3:303-309.
33. Ashkenazi A, Dixit VM: Death receptors: Signaling and modulation. Science 1998;281: 1305-1308.
34. Schlessinger J, Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron 1992; 9:383-391.
35. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-212.
36. Pawson T: Tyrosine kinases and their interactions with signaling proteins. Curr Opin Genet Dev 1992;2:4-12.
37. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T: SHw and SH3 domains: Elements that control interactions of cytoplasmic signaling proteins. Science 1991;252:668-674.
38. Pawson T: Protein modules and signalling networks. Nature 1995;373:573-580.
39. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 1993;366: 643-654.
40. McCormick F: How receptors turn Ras on. Nature 1993;363:15-16.
41. Dickson B, Sprenger F, Morrison D, Hafen E: Raf functions downstream of Ras1 in the Sevenless signal transduction pathway. Nature 1992;360:600-603.
42. Songyang Z, Carraway KL III, Eck MJ, Harrison SC, Feldman RA, Mohammed M, Schlessinger J, Hubbard SR, Smith DP, Eng C, Lorenzo MJ, Ponder BAJ, Mayer BJ, Cantley LC: Catalytic specificity of protein-tyrosine kinases is critical for selective signaling. Nature 1995; 373:536-539.
43. Li N, Batzer A, Daly R, Yajnik V, Skolnik E, Chardin P, Bar-Sagi D, Margolis B, Schlessinger J: Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signaling. Nature 1993;363: 85-88.
44. Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D: The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 1993;363: 83-85.
45. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, Batzer A, Thomas S, Brugge J, Pelicci PG, Schlessinger J, Pawson T: Association of the She and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 1992;360:689-692.
46. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J: A role of Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 1996;383:547-550.
47. Ihle JN: Cytokine receptor signalling. Nature 1995;377:591-594.
48. Marais R, Light Y, Mason C, Paterson H, Olson MF, Marshall CJ: Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science 1998;280:109-112.
49. Berridge MJ: Inositol triphosphate and calcium signalling. Nature 1993;361:315-325.
50. Meisenhelder J, Suh P-G, Rhee S-G, Hunter T: Phospholipase C-γ is a substitute for the PDGR and EGF receptor protein-tyrosine kinases in vivo and in vitro. Cell 1989;57:1109-1122.
51. Kauffmann-Zeh A, Thomas GMH, Ball A, Prosser S, Cunningham E, Cockcroft S, Hsuan JJ: Requirement for phosphatidylinositol transfer protein in epidermal growth factor signaling. Science 1995;368:1188-1190.
52. Hu Q, Klippel A, Muslin AJ, Fantl WJ, Williams LT: Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 1995;268:100-102.
53. Shual K, Ziemiecki A, Wilks AF, Harpur AG, Sadowski HB, Gilman MZ, Darnell JE: Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature 1993;366:580-585.
54. Zhong Z, Wen Z, Darnell JE Jr: Stats: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95-98.
55. Watling D, Guschin D, Muller M, Silvennoinen O, Witthuhn BA, Quelle FW, Rogers NC, Schindler C, Stark GR, Ihle JN, Kerr IM: Complementation by the protein tyrosine kinase JAK2 mutant cell line defective in the interferron-γ signal transduction pathway. Nature 1993;366:166-170.
56. Luo Z, Tzivion G, Belshaw PJ, Vavvas D, Marshall M, Avruch J: Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 1996;383:181-185.
57. Freed E, Symons M, MacDonald SG, McCormick F, Ruggieri R: Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. Science 1994;265:1713-1716.
58. Kyriakis JM, App H, Zhang X-f, Banerjee P, Brautigan DL, Rapp UR, Avruch J: Raf-1 activates MAP kinase-kinase. Nature 1992;358: 417-421.
59. Derijard B, Raingeaud J, Barrett T, Wu I-H, Han J, Ulevitch RJ, Davis RJ: Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995;367:682-684.
60. Adams PD, Parker PJ: Activation of Mitogen-activated protein (MAP) kinase by a MAP kinase-kinase. J Biol Chem 1992;267:13135-13137.
61. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994;265:966-970.
62. TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 1992;358:414-417.
63. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR: Phosphorylation of c-jun mediated by MAP kinases. Nature 1991;353: 670-674.
64. Blenis J: Signal transduction via the MAP kinases: Proceed at your own RSK. Proc Natl Acad Sci USA 1993;90:5889-5892.
65. Gille H, Kortenjahn M, Thomae O, Moomaw C, Slaughter C, Cobb MH, Shaw PE: ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 1995;14:951-962.
66. Marais R, Wynne J, Treisman R: The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 1993;73:381-393.
67. Lin A, Minden A, Martinetto H, Claret F-X, Lange-Carter C, Mercurio F, Johnson GL, Karin M: Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 1995;268:286-290.
68. Sanchez I, Hughes RT, Mayer BJ, Yee K, Woodgett JR, Avruch J, Kyriakis JM, Zon LJ: Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 1994;372:794-798.
69. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL, Karin M: Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 1994;266:1719-1723.
70. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA: Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997;16:1909-1920.
71. Ludwig S, Engel K, Hoffmeyer A, Sithanandam G, Neufeld B, Palm D, Gaestel M, Rapp UR: 3pK, a novel mitogen-activated protein (MAP kinase-activated protein kinase, is targeted by three MAP kinase pathways. Mol Cell Biol 1996;16:6687-6697.
72. Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW: Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science 1993;262: 1065-1069.
73. Cook SJ, McCormick F: Inhibition by cAMP of Ras-dependent activation of Raf. Science 1993;262:1069-1072.
74. Gilman AG: G proteins and regulation of adenylyl cyclase. JAMA 1989;262:1819-1825.
75. Levitzki A, Gazit A: Tyrosine kinase inhibition: an approach to drug development. Science 1995;267:1782-1788.
76. Kelloff GJ, Fay JR, Steele VE, Lubet RA, Boone CW, Crowell JA, Sigman CC: Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prevent 1996; 65:657-666.
77. Shawver LK, Schwartz DP, Mann E, Chen H, Tsai JM, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon B, Hirth KP: Inhibiton of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]-5-methylisoxazole-4-carboxamide. Clin Cancer Res 1997;3:1167-1177.
78. Takai Y, Kishimoto A, Inoue M, Nishizuka Y: Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissue. I. Purification and characterization of an active enzyme from bovine cerebellum. J Biol Chem 1977;252:7603-7609.
79. Nishizuka Y: The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature 1984;308:693-695.
80. Nishizuka Y: The molecular heterogenity of protein kinase C and its implications for cellular regulation. Nature 1988;334:661-665.
81. Kiley SC, Jaken S, Whelan R, Parker PJ: Intracellular targeting of protein kinase C isoenzymes, functional implications. Biochem Soc Trans 1995;23:601-605.
82. Basu A, Lazo JS: Protein kinase C; in Kerr DJ, Workman P (eds): Boca Raton, CRC Press, 1994, pp 121-141.
83. Koide H, Ogita K, Kikkawa U, Nishizuka Y: Isolation and characterization of the epsilon subspecies of protein kinase C from rat brain. Proc Natl Acad Sci USA 1992;89:1149-1153.
84. Liyanage M, Frith D, Livneh E, Stabel S: Protein kinase C group B members PKC-delta, -epsilon, -zeta and PKC-L(eta). Comparison of properties of recombinant proteins in vitro and in vivo. Biochem J 1992;283:781-787.
85. Ogita K, Miyamoto S, Yamaguchi K, Koide H, Fujisawa N, Kikkawa U, Sahara S, Fukami Y, Nishizuka Y: Isolation and characterization of delta-subspecies of protein kinase C form rat brain. Proc Natl Acad Sci USA 1992;89:1592-1596.
86. Osada SI, Mizuno K, Saido TC, Atita Y, Suzuki K, Kuroki T, Ohno S: A phorbol ester receptor/protein kinase, nPKC eta, a new member of the protein kinase C family predominantly expressed in lung and skin. J Biol Chem 1990; 265:22434-22440.
87. Soderling TR: Protein kinases. Regulation by autoinhibitory domains. J Biol Chem 1990; 265:1823-1826.
88. Orr JW, Kranen LM, Newton AC: Reversible exposure of the pseudosubstrate domain of protein kinase C by phosphatidylserine and diacylglycerol. J Biol Chem 1992;267:15263-15266.
89. Ha KS, Exton JH: Different translocation of protein kinase C isozymes by thrombin and platelet-derived growth factor. A possible function for phosphatidylcholine-derived diacylglycerol. J Biol Chem 1993;268:10534-10539.
90. Olivier AR, Parker PJ: Bombesin, platelet-derived growth factor, and diacylglycerol induce selective membrane association and down-regulation of protein kinase C isotypes in Swiss 3T3 cells. J Biol Chem 1994;269: 2758-2763.
91. Berridge MJ, Irvine RF: Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 1994;312:315-321.
92. Billah MM, Anthes JC: The regulation and cellular functions of phosphatidylcholine hydrolysis. Biochem J 1990;269:281-291.
93. Exton JH: Signaling through posphatidylcholine breakdown. J Biol Chem 1990;265:1-4.
94. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1990;258:607-613.
95. Kishimoto A, Takai Y, Mori T, Kikkawa U, Nishizuka Y: Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. J Biol Chem 1980;255: 2273-2276.
96. Blumberg PM: Protein kinase C as the receptor for the phorbol ester tumor promoters. Cancer Res 1988;48:1-8.
97. Kikkawa U, Takai Y, Tanaka Y, Miyake R, Nishizuka Y: Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. J Biol Chem 1983;258:11442-11445.
98. Missiaen L, Taylor CW, Berridge MJ: Spontaneous calcium release from inositol trisphosphate-sensitive calcium stores. Nature 1991; 352:241-244.
99. Ras generated signals towards cell growth or apoptosis is determined by protein kinase C and bcl-2. Oncogene 1995;11:1487-1498.
100. Kiss Z, Deli E, Kuo JF: Temporal changes in intracellular distribution of protein kinase C during differentiation of human leukemia HL 60 cells induced by phorbol ester. FEBS Lett 1988;231:41-46.
101. Kolch W, Heldecker G, Kochs G, Hummel R, Vahldl H, Mischak H, Finkenzeller G, Marme D, Rapp UR: Protein kinase Calpha activates Raf-1 by direct phosphorylation. Nature 1993;364:249-252.
102. Chao T-SO, Foster DA, Rapp UR, Rosner MR: Differential raf requirement for activation of mitogen-activated protein kinase by growth factors, phorbol esters, and calcium. J Biol Chem 1994;269:7337-7341.
103. Susa M, Olivier AR, Fabbro D, Thomas G: EGF induces biphasic S6 kinase activation: late phase is protein kinase C-dependent and contributes to mitogenicity. Cell 1989;57: 817-824.
104. Livneh E, Fishman DD: Linking protein kinase C to cell-cycle control. Eur J Biochem 1997;248:1-9.
105. Niedler JE, Kuhn LJ, Vandenbark GR: Phorbol diester receptor co-purifies with protein kinase C. Proc Natl Acad Sci USA 1983;80: 36-40.
106. Colburn NH, Former BF, Nelsen KA, Yuspa SH: Tumor promotor induces anchorage independence irreversibly. Nature 1979;281: 589-591.
107. Drieger PE, Blumberg PM: The effect of phorbol esters on chicken embryo fibroblasts. Cancer Res 1977;37:3257-3265.
108. Housey GM, Johnson MD, Hsiao WLW, O'Brian CA, Murphy JP, Kishmeier P, Weinstein IB: Overproduction of protein kinase C causes disordered growth on rat fibroblasts. Cell 1988;52:343-354.
109. Persons DA, Wilkinson WO, Bell RM, Finne OJ: Altered growth regulation and enhanced tumorigenicity of NIH 3T3 fibroblasts transfected with protein kinase C-1 cDNA. Cell 1988;52:447-458.
110. Choi PM, Tchou-Wong K-M, Weinstein B: Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression. Mol Cell Biol 1990; 10:4650-4657.
111. Yamanishi DT, Graham M, Buckmeier JA, Meykens FL: The differential expression of protein kinase C genes in normal human neonatal melanocytes and metastatic melanomas. Carcinogenesis 1991;12:105-109.
112. Eldar H, Zisman Y, Ullrich A, Livneh E: Overexpression of protein kinase Ca-subtype in swiss/3T3 fibroblasts causes loss of both high and low affinity receptor numbers of epidermal growth factor. J Biol Chem 1990;265: 13290-13296.
113. Cacace AM, Guadagno SN, Krauss RS, Fabbro D, Weinstein IB: The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene 1993;8: 2095-2104.
114. Mischak H, Goodnight J, Kolch W, et al: Overexpression on protein kinase C-δ and ε in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem 1993; 268:6090-6096.
115. O'Brian CA, Vogel VG, Sinletary SE, Ward NE: Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 1989;49:3215-3217.
116. 2+-dependent protein kinases in human colon carcinomas. Cancer Res 1987;47:2036-2039.
117. Kopp R, Neolke B, Sauter G, Schildberg FW, Paumgartner G, Pfeiffer A: Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas. Cancer Res 1991; 51:205-210.
118. Aflalo E, Wolfson M, Ofir R, Weinstein Y: Elevated activities of protein kinase C and tyrosine kinase correlate to leukemic cell aggressiveness. Int J Cancer 1992;50:136-141.
119. Schwartz GK, Redwood SM, Ohnuma T, et al: Inhibition of invasive human bladder carcinoma cells by protein kinase C inhibitor staurosporine. J Natl Cancer Inst 1990;82: 1753-1756.
120. Dekker LV, Parker PJ: Protein kinase C-A question of specificity. Trends Biochem Sci 1994;19:73-77.
121. Diaz-Laviada I, Larrodera P, Diaz-Meco MT, Cornet ME, Guddal PH, Johansen T, Moscat J: Evidence for a role of phosphatidylcholinehydrolysing phospholipase C in the regulation of protein kinase C by ras and src oncogenes. EMBO J 1990;9:3907-3912.
122. Huang M, Chida K, Kamata N, Nose K, Kato M, Homma Y, Takenawa T, Kuroki T: Enhancement of inositol phospholipid metabolism and activation of protein kinase C in ras-transformed rat fibroblasts. J Biol Chem 1988;263:17975-17980.
123. Price BD, Morris JDH, Marshall CJ, Hall A: Stimulation of phosphatidylcholine hydrolysis, diacylglycerol release, and arachidonic acid production by oncogenic ras is a consequence of protein kinase C activation. J Biol Chem 1989;264:16638-16643.
124. Hashimoto T, Ase K, Sawamura S, Kikkawa U, Saito N, Tanaka C, Nishizuka Y: Postnatal development of brain-specific subspecies of protein kinase C in rat. J Neurosci 1988;8: 1678-1683.
125. Hocevar BA, Fields AP: Selective translocation of βII-protein kinase C to the nucleus of human promyelocytic (HL-60) leukemia cells. J Biol Chem 1991;266:28-33.
126. Neary JT, Norenberg OB, Norenberg MD: Protein kinase C in primary astrocyte cultures: Cytoplasmic localization and translocation by a phorbol ester. J Neurochem 1988; 50:1179-1184.
127. Brandt SJ, Niedel JE, Bell RM, et al: Distinct patterns of expression of different protein kinase C mRNAs in rat tissue. Cell 1987;49: 57-63.
128. Clark EA, Leach KL, Trojanowski JQ, et al: Characterization and differential distribution of the three major protein kinase C isozymes of the central nervous system in normal and Alzheimer's disease brains. Lab Invest 1991; 64:35-44.
129. Masliah E, Cole G, Shimohama S, et al: Differential involvement of protein kinase C isozymes in Alzheimer's disease. J Neurosci 1990;10:2113-2124.
130. Baltuch GH, Dooley NP, Rostworowski KM, Villemure J-G, Yong VW: Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation. J Neurooncol 1995;24:241-250.
131. Baltuch GH, Dooley NP, Villemure JG, Yong VW: Protein kinase C and growth regulation of malignant gliomas. Can J Neurol Sci 1995; 22:264-271.
132. Benzil DL, Finkelstein SD, Epstein MH, Finch PW: Expression pattern of alpha-protein kinase C in human astrocytomas indicates a role in malignant progression. Cancer Res 1992;52:2951-2956.
133. Couldwell WT, Antel JP, Yong VW: Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 1992;31:717-724.
134. Couldwell WT, Hinton DR, Law RE: Protein kinase C and growth regulation in malignant gliomas. Neurosurgery 1994;35:1184-1186.
135. Couldwell WT, Uhm JH, Antel JP, Young VW: Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery 1991;29:880-887.
136. Pollack IF, Kawecki S: Patterns of growth factor, growth factor receptor, and second messenger expression in pediatric brain tumors. J Neurosurg 1994;80:400A.
137. Baltuch GH, Yong VW: Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway. Brain Res 1996;710:143-149.
138. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Jr: Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways. J Neurosurg 1990;73:98-105.
139. Baltuch GH, Couldwell WT, Villemure JG, Yong VW: Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery 1993;33:495-501.
140. Begemann M, Kashimawo SA, Choi YJA, Kim S, Christiansen KM, Duigou G, Mueller M, Schieren I, Ghosh S, Fabbro D, Lampen NM, Heitjan DF, Schiff PB, Bruce JN, Weinstein IB: Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. Clin Cancer Res 1996;2:1017-1030.
141. Bredel M, Pollack IF, Freund JM, Rusnak J, Lazo JS: Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion. J Neurooncol 1998; in press.
142. Couldwell WT, Antel JP, Apuzzo MLJ, Young VW: Inhibition of growth of established human glioma cell lines by modulators of the protein kinase C system. J Neurosurg 1990;73:594-600.
143. Pollack IF, Kawecki S: The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors. Pediatr Neurosurg 1995;22:281-288.
144. Pollack IF, Kawecki S, Lazo JS: Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J Neurosurg 1996;84:1024-1032.
145. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Jr: Effects of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 1990;50:7134-7138.
146. Reifenberger G, Deckert M, Wechsler W: Immunohistochemical determination of protein kinase C expression and proliferative activity in human brain tumors. Acta Neuropathol 1989;78:166-175.
147. Todo T, Shitara N, Nakamura H, Takakura K, Ikeda K: Immunohistochemical demonstration of protein kinase C isozymes in human brain tumors. Neurosurgery 1991;29: 399-404.
148. 6 glioma cells. TPA induces translocation and down-regulation of conventional and new PKC isoforms but not atypical PKCζ. FEBS Lett 1993;332:169-173.
149. Ahmad S, Mineta T, Martuza RL, Glazer RI: Antisense expression of protein kinase C-alpha inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery 1994;35:904-909.
150. Dooley NP, Baltuch GB, Paton A, et al: Phosphothioate antisense oligonucleotides to protein kinase Cα inhibit proliferation in rat C6 glioma (abstract). Proc Annu Meet Am Assoc Cancer Res 1994;35:3375.
151. Yazaki T, Ahmad S, Chahlavi A, Zylberkatz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α phosphorothioate oligodeoxynucleotide. Mol Pharmacol 1996;50:236-242.
152. Pollack IF, DaRossa R, Robertson P, Jackaki R, Mirro J Jr, Blatt J, Nicholson S, Packer RJ, Allen JC, Jordan CV: A phase I/II study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 1997;3:1109-1115.
153. Baltuch GH, Shenouda G, Langleben A, Villemure J-G: High dose tamoxifen in the treatment of recurrent high grade glioma: A report of clinical stabilization and tumour regression. Can J Neurol Sci 1993;20:168-170.
154. Couldwell WT, Hinton DR, Surnock AA, Degiorgio CM, Weiner LP, Apuzzo MLJ, Masri L, Law RE, Weiss MH: Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996; 2:619-622.
155. Couldwell WT, Weiss MH, DeGiorgio CM, Weiner LP, Hinton DR, Ehresmann GR, Conti PS, Apuzzo ML: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993;32: 485-490.
156. 1H-MR spectroscopic imaging. J Neurosurg 1993;80: 413A.
157. Vertosick FT Jr, Selker RG, Arena V: A dose-escalation study of tamoxifen therapy in patients with recurrent glioblastoma multiforme (abstract). J Neurosurg 1994;80:385A.
158. Vertosick FT Jr, Selker RG, Pollack IF, Arena V: The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: Preliminary results in a series of 'failed' patients. Neurosurgery 1992;30:897-903.
159. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M: Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991;51:4888-4892.
160. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH, Law RE: Protein kinase C inhibitors induce apoptosis in human malignant gioma cell lines. FEBS Lett 1994;345: 43-46.
161. Bredel M, Pollack IF, Freund JM, Rusnak JM, Lazo JS: UCN-01-mediated down-regulation of protein kinase C (PKC) blocks malignant glioma proliferation and induces apoptosis independent of p53, but dependent on IL-1β converting enzyme. Zentralbl Neurochir 1998; in press.
162. Ikemoto H, Tani E, Matsumoto T, Nakano A, Furuyama J: Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. J Neurosurg 1995;83: 1008-1016.
163. Chambers TC, Chalikonda I, Elion G: Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells. Biochem Biophys Res Commun 1990;169:253-259.
164. Fine RL, Patel J, Chabner BA: Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 1988; 85:582-586.
165. Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki K, Tsuruo T, Cowan KH, Glazer RI: Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 1991;3:181-189.
166. Miyamoto KI, Wakusawa S, Inoko K, Takagi K, Koyama M: Reversal of vinblastine resistance by a new staurosporine derivate, NA-382 in P388/ADR cells. Cancer Lett 1992;64: 177-183.
167. Basu A, Lazo JS: Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum (II) by bryostatin 1. Cancer Res 1992;52:3119-3124.
168. Basu A, Teicher BA, Lazo JS: Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum (II). J Biol Chem 1990;265: 8451-8457.
169. Bunch RT, Eastman A: Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 1996;2:791-797.
170. Akinaga S, Akiyama T, Shimizu M, Okabe M: G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and cdk-2, as well as induction of cdk inhibitor p21 in p53-mutated human carcinoma cells (abstract). Proc Annu Meet Am Assoc Cancer Res 1996;37:2888.
171. Akinaga S, Nomura K, Gomi K, Okabe M: Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma. A431 cells. Cancer Chemother Pharmacol 1994;33:273-280.
172. Nigg EA, Kreak W, Peter M: Vertebrate cdc2 kinase its regulation by phosphorylation and its mitotic targets. Cold Spring Harbor Symp Quant Biol 1991;56:539-547.
173. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ: Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 1993;53:2081-2086.
174. Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ: The ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem 1997;272:16093-16095.
175. Lebowitz PF, Casey PJ, Prendergrast GC, Thissen JA: Farnesyltransferase inhibitors alter the prenylation and growth stimulating function of RhoB. J Biol Chem 1997;272: 15591-15594.
176. Boguski MS, McCormick F: Proteins regulation Ras and its relatives. Nature 1993;366: 643-654.
177. Bollag G, McCormick F: Differential regulation of Ras-GAP and neurofibromatosis gene product activities. Nature 1991;351:576-579.
178. McCormick F: Ras signaling and NF1. Curr Opin Genet Dev 1995;5:51-55.
179. Xu GF, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R, White R, Weiss R: The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990;62:599-608.
180. Casay PJ: Biochemistry of protein prenylation. J Lipid Res 1992;33:1731-1740.
181. Reiss Y, Stradley SJ, Gierasch LM, Brown MS, Goldstein JL: Sequence requirement for peptide recognition by rat brain p21-Ras protein farnesyltransferase. Proc Natl Acad Sci USA 1991;88:732-736.
182. Marshall CJ: Protein prenylation: A mediator of protein-protein interactions. Science 1993; 259:1865-1866.
183. Yokoyama K, Goodwin GW, Ghomashchi F, Glomset JA, Gelb MH: A protein geranylgeranyltransferase from bovine brain: Implications for protein prenylation specificity. Proc Natl Acad Sci USA 1991;88:5302-5306.
184. Hancock JF, Paterson H, Marshall JC: A polybasic domain for palmitoylation is required in addition to CAAX motif to localize p21-Ras to the plasma membrane. Cell 1990; 63:133-139.
185. Harvey JJ: An unidentified virus which causes the rapid production of tumors in mice. Nature 1964;204:1104-1105.
186. Kirsten WH, Mayer LA: Morphological responses to a murine erythroblastosis virus. J Natl Cancer Inst 1967;39:311-335.
187. Bos JL: Ras oncogenes in human cancers: A review. Cancer Res 1989;49:4682-4689.
188. Peddanna N, Mendis R, Holt S, Verma RS: Genetics of colorectal cancer (review). Int J Oncol 1996;9:327-335.
189. Caldas C, Kern SE: K-ras mutations and pancreatic adenocarcinoma. Int J Pancreatol 1995;18:1-6.
190. Pinto MM, Emanuel JR, Chaturvedi V, Costa J: K-Ras mutations and the carcinoembryonic antigen level in fine needle aspirates of the pancreas. Acta Cytol 1997;41:427-434.
191. Johnson BE, Kelley MJ: Overview of genetic and molecular events in the pathogenesis of lung cancer. Chest 1993;103:1-3.
192. Maltzman TH, Mueller BA, Schroeder J, Rutledge JC, Patterson K, Preston-Martin S, Faustman EM: Ras oncogene mutations in childhood brain tumors. Cancer Epidemiol Biomarkers Prev 1997;6:239-243.
193. Lang FF, Miller CC, Koslow M, Newcomb EW: Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994;81:427-436.
194. Gerosa MA, Talarico D, Fognani C, Raimondi E, Colombatti M, Tridente G, De Carli L, Della Valle G: Overexpression of N-ras oncogene and epidermal growth factor receptor gene in human glioblastomas. J Natl Cancer Inst 1989;81:63-67.
195. Guha A, Lau N, Pawson A: Ras-mediated proliferation of human astrocytoma cells (abstract). Proc Annu Meet Am Assoc Cancer Res 1995;36:1029.
196. Gutmann DH, Giordano MJ, Mahadeo DK, Lau N, Silbergeld D, Guha A: Increased neurofibromatosis 1 gene expression in astrocytic tumors: Positive regulation by p21-ras. Oncogene 1996;12:2121-2127.
197. Orian JM, Vasilopoulos K, Yoshida S, Kaye AH, Chow CW, Gonzales MF: Overexpression of multiple oncogenes related to histopathological grade of astrocytic glioma. Br J Cancer 1992;66:106-112.
198. Riccardi A, Danova M, Giordano M, Gaetani P, Butti G, Zibera C, Mazzini G: Proto-oncogene expression and proliferative activity in human malignant gliomas. Dev Oncol 1991; 66:81-84.
199. Salgaller M, Agius L, Yates A, Pearl D, Roberts W, Stephens R: Application of automated image analysis to demonstrate the correlation between Ras p21 expression and severity of gliomas. Biochem Biophys Res Commun 1990;169:482-491.
200. Feldkamp MM, Lau N, Guha A: Signal tansduction pathways and their relevance in human astrocytomas. J Neurooncol 1997;35: 223-248.
201. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HJS: Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediate through the Ras-SHC-GRB2 pathway. J Biol Chem 1996;271:25639-25645.
202. Lerner EC, Qian Y, Blaskovitch MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM: Ras CAAX peptidomimetic FTI-277 blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 1995; 270:26802-26806.
203. Lerner EC, Qian Y, Hamilton AD, Sebti SM: Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 1995;270: 26770-26773.
204. 2-M enrichment in A549 cells. Cancer Res 1997;57:1846-1850.
205. Sebti SM, Hamilton D: Inhibition of Ras prenylation: A novel approach to cancer chemotherapy. Pharmacol Ther 1997;74:103-114.
206. Sun J, Qian Y, Hamilton AD, Sebti SM: Ras CAAX peptidomimetic FTI-276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 1995;55:4243-4247.
207. Kohl NE, Conner MW, Gibbs JB, Graham SL, Hartman GD, Oliff A: Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J Cell Biochem 1995;22:145-150.
208. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM: Inhibition of human tumor xenograft growth by treatment with farnesyl transferase inhibitor B956. Cancer Res 1995; 55:5310-5314.
209. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N: A peptidomimetic inhibitor of farnesylprotein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995;55:5302-5309.
210. Pollack IF, Bredel M, Freund JM, Sebti SM: Blockade of malignant glioma proliferation by inhibiting p21-Ras. Proc Annu Meet Am Assoc Cancer Res 1997;38:351-352.
211. Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM: Inhibition of ras and related G-proteins as a novel therapeutic strategy for blocking malignant glioma growth. Neurosurgery 1998;43:124-132.
212. Lebowitz PF, Sakamuro D, Prendergrast GC: Farnesyl transferase inhibitors induce apoptosis of ras-transformed cells denied substratum attachment. Cancer Res 1997;57:708-713.
213. WAF1/CIP1/DSI1 in a p53-independent manner. J Biol Chem 1997;272: 27224-27229.